Trials / Completed
CompletedNCT01242098
Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management
Retrospective, Real-life Observational, Matched Cohort Evaluation of the Effectiveness of BDP/FOR (Fostair® 100/6) and FP/SAL (Seretide® 125) in Patients Switching From Seretide to Fostair in UK Primary Care Asthma Management
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 137 (actual)
- Sponsor
- Research in Real-Life Ltd · Network
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fixed dose combination salmeterol / fluticasone | Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy |
| DRUG | Fixed-dose combination beclometasone dipropionate / formoterol | Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2010-11-16
- Last updated
- 2012-06-08
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01242098. Inclusion in this directory is not an endorsement.